Key Findings from the INTERCEPT Study

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.